NCT00104663

PRION-1: Quinacrine for Human Prion Disease. A Partially Randomized Patient Preference Trial to Evaluate the Activity and Safety of Quinacrine in Human Prion Disease

Completed NA Last updated 6 April 2015

What this trial tests

NA trial testing Quinacrine in Prion Disease in 160 participants. Completed in 1 March 2007.

Timeline

1 June 2004

1 March 2007

Quick facts

Lead sponsor	Medical Research Council
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	160
Start date	1 June 2004
Estimated completion	1 March 2007
Sites	1 location across United Kingdom

Drugs / interventions tested

• Quinacrine — full drug profile →

Conditions studied

• Prion Disease — all drugs for Prion Disease →

Sponsor

Medical Research Council

Who can join

12 and older, any sex, with Prion Disease. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

• Time to death
• proportion of responders, with "responders" defined as patients showing either clinical improvement or lack of deterioration in 3 key neurological and neuropsychiatric measures

Sponsor's own description

PRION-1 aims to assess the activity and safety of Quinacrine (Mepacrine hydrochloride) in human prion disease. It also aims to establish an appropriate framework for the clinical assessment of therapeutic options for human prion disease that can be refined or expanded in the future, as new agents become available.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

1. Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases.
   Al-Bari MA. · · 2015 · cited 293× · PMID 25693996 · DOI 10.1093/jac/dkv018
2. Beyond DNA binding - a review of the potential mechanisms mediating quinacrine's therapeutic activities in parasitic infections, inflammation, and cancers.
   Ehsanian R, Van Waes C, Feller SM. · · 2011 · cited 98× · PMID 21569639 · DOI 10.1186/1478-811x-9-13
3. Quinacrine, an Antimalarial Drug with Strong Activity Inhibiting SARS-CoV-2 Viral Replication In Vitro.
   Salas Rojas M, Silva Garcia R, Bini E, Pérez de la Cruz V, et al · · 2021 · cited 17× · PMID 33477376 · DOI 10.3390/v13010121
4. Quinacrine, an Old Drug with Potentially usefull in the Treatment for COVID-19.
   Pineda B. · · 2021 · cited 1× · PMID 34154830 · DOI 10.1016/j.arcmed.2021.06.002